Publications

Export 18 results:
Author Title [ Type(Asc)] Year
Filters: Author is Kennedy, Sidney H  [Clear All Filters]
Journal Article
Fiori LM, Orri M, Aouabed Z, Théroux JFrançois, Lin R, Nagy C, Frey BN, Lam RW, Macqueen GM, Milev R et al..  2021.  Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.. Transl Psychiatry. 11(1):439.
Uher R, Frey BN, Quilty LC, Rotzinger S, Blier P, Foster JA, Müller DJ, Ravindran AV, Soares CN, Turecki G et al..  2020.  Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.. J Clin Psychiatry. 81(4)
Phillips JL, Jaworska N, Kamler E, Bhat V, Blier J, Foster JA, Hassel S, Ho K, McMurray L, Milev R et al..  2020.  A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.. BMC Psychiatry. 20(1):268.
Belzeaux R, Fiori LM, Lopez JPablo, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW et al..  2019.  Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3)
Saeedi S, Nagy C, Ibrahim P, Théroux J-F, Wakid M, Fiori LM, Yang J, Rotzinger S, Foster JA, Mechawar N et al..  2021.  Neuron-derived extracellular vesicles enriched from plasma show altered size and miRNA cargo as a function of antidepressant drug response.. Mol Psychiatry.
Lopez JPablo, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C et al..  2017.  MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.
Caspani G, Turecki G, Lam RW, Milev RV, Frey BN, Macqueen GM, Müller DJ, Rotzinger S, Kennedy SH, Foster JA et al..  2021.  Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report.. Commun Biol. 4(1):903.
Fiori LM, Lopez JPablo, Richard-Devantoy S, Berlim M, Chachamovich E, Jollant F, Foster J, Rotzinger S, Kennedy SH, Turecki G.  2017.  Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.. Int J Neuropsychopharmacol. 20(8):619-623.
Ju C, Fiori LM, Belzeaux R, Théroux J-F, Chen GGang, Aouabed Z, Blier P, Farzan F, Frey BN, Giacobbe P et al..  2019.  Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.
Suh JSu, Fiori LM, Ali M, Harkness KL, Ramonas M, Minuzzi L, Hassel S, Strother SC, Zamyadi M, Arnott SR et al..  2021.  Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report.. Psychoneuroendocrinology. 132:105348.
Belzeaux R, Gorgievski V, Fiori LM, Lopez JPablo, Grenier J, Lin R, Nagy C, Ibrahim EChérif, Gascon E, Courtet P et al..  2020.  GPR56/ADGRG1 is associated with response to antidepressant treatment.. Nat Commun. 11(1):1635.
Marshe VS, Maciukiewicz M, Hauschild A-C, Islam F, Qin L, Tiwari AK, Sibille E, Blumberger DM, Karp JF, Flint AJ et al..  2021.  Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response.. Transl Psychiatry. 11(1):127.
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR et al..  2016.  Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.
Baskaran A, Farzan F, Milev R, Brenner CA, Alturi S, McAndrews MPat, Blier P, Evans K, Foster JA, Frey BN et al..  2017.  The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.
Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P et al..  2005.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.. Bipolar Disord. 7 Suppl 3:5-69.
Kennedy SH, Lam RW, McIntyre RS, S Tourjman V, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, Macqueen GM et al..  2016.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.. Can J Psychiatry. 61(9):540-60.
Yrondi A, Fiori LM, Nogovitsyn N, Hassel S, Théroux JFrançois, Aouabed Z, Frey BN, Lam RW, Milev R, Müller DJ et al..  2021.  Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report.. Transl Psychiatry. 11(1):469.
Yrondi A, Fiori LM, Frey BN, Lam RW, Macqueen GM, Milev R, Müller DJ, Foster JA, Kennedy SH, Turecki G.  2019.  Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report.. Int J Neuropsychopharmacol.